Monday, March 3rd, 2008
Micrus Endovascular Corporation (Nasdaq: MEND) announced that management will make presentations at four investment conferences in March:
- Robert Stern, Micrus President and COO, will present at the Rodman & Renshaw "Straight to the Heart" one-day, one-on-one meeting conference on Tuesday, March 4. The conference will be held at the Boston ...
Posted in Neurology / Neuroscience | No Comments »
Tuesday, February 26th, 2008
Up to 20 percent of patients taking aspirin to lower the risk of suffering a second cerebrovascular event do not have an antiplatelet response from aspirin, the effect thought to produce the protective effect, researchers at the University at Buffalo have shown.
"Millions of people use low-dose aspirin either for prevention ...
Posted in Stroke / Neuroprotection | No Comments »
Tuesday, February 26th, 2008
According to an article published in the April edition of The Lancet Neurology, donepezil may improve the executive function of patients who suffer from the CADASIL form of vascular dementia. However, researcher Martin Dichgans of Ludwig Maximilian University, Munich, Germany and colleagues found that donepezil did not improve patients' cognitive ...
Posted in Alzheimers / Dementia | No Comments »
Monday, February 25th, 2008
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has received notification of European Patent Office (EPO) approval for technology to which Corgenix holds exclusive worldwide licensing rights.
McMaster University (McMaster) of Hamilton, Ontario, is the owner of the patent covering the aspirin resistance measurement method. ...
Posted in Medical Devices | No Comments »
Monday, February 25th, 2008
American adults have a higher prevalence of stroke than their European counterparts, due in part to a higher rate of stroke risk factors among Americans and barriers to care in the United States, according to a study presented at the American Stroke Association's International Stroke Conference 2008.
Compared to European men, ...
Posted in Stroke / Neuroprotection | No Comments »
Saturday, February 23rd, 2008
According to an article published in The Lacnet Neurology, phase III clinical trials of alteplase should now begin. Alteplase is the only licensed therapy for acute ischaemic stroke and is found to have positive effects for some patients, even if administered after the usual 3-hour treatment window.
Acute ischaemic stroke is ...
Posted in Stroke / Neuroprotection | No Comments »
Saturday, February 23rd, 2008
A new US study found that dozing during the day could be a sign of increased stroke risk for elderly Americans. The findings of the study (Abstract 94) were presented to the American Stroke Association's International Stroke Conference 2008, taking place in New Orleans this week.
The researchers found that stroke ...
Posted in Stroke / Neuroprotection | No Comments »
Friday, February 22nd, 2008
A new US study found that dozing during the day could be a sign of increased stroke risk for elderly Americans. The findings of the study (Abstract 94) were presented to the American Stroke Association's International Stroke Conference 2008, taking place in New Orleans this week.
The researchers found that stroke ...
Posted in Stroke / Neuroprotection | No Comments »
Friday, February 22nd, 2008
Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) is pleased to announce favorable results from the investigator led BETAS (Beta-hCG + Erythropoietin in Acute Stroke), Phase IIa, open label, safety trial conducted at the University of California, Irvine and Hoag Presbyterian Memorial Hospital, Newport Beach, CA. This trial is the first ...
Posted in Stroke / Neuroprotection | No Comments »
